Introduction
Glucocorticoids in excess cause hyperglycemia and hyperinsulinemia in the basal state and after oral glucose ingestion (1) . This insulin-resistant state primarily involves post-receptor defects in peripheral tissues (impaired glucose transport) (2) . However, some studies indicate that insulin resistance also exists at the hepatic level, with elevated basal glucose production after 7 d of steroid administration (3) , and increased hepatic glucose output after cortisol infusion (4) . The effect ofsteroids on hepatic uptake of glucose after its oral administration has not been examined previously. Although glucocorticoids directly inhibit insulin secretion (4) (5) (6) (7) (8) (9) , the hyperinsulinemia has been attributed to enhancement of stimulation of the B cell by the elevated glucose concentrations that result from insulin resistance (10) . The present study examined the possibility that dexamethasone might alter the fractional hepatic extraction of insulin, thereby contributing to the hyperinsulinemia and the effect of the steroid on hepatic glucose metabolism after oral glucose administration.
Methods

Animals and surgery
Healthy adult male and female mongrel dogs weighing 18-30 kg were anesthetized with intravenous sodium pentobarbitol (25 mg/kg body wt) (1 1) . The blood flow measurements were corrected to plasma flow based on hematocrits obtained every 30 min, since glucose, insulin, and glucagon were measured in plasma. Blood samples were collected in chilled tubes containing 500 U Trasylol (Mobay Chemical Corp., New York) and 1.2 mg EDTA/mI blood. Plasma immunoreactive insulin was assayed using dextran-coated charcoal (15) . Plasma immunoreactive glucagon was assayed with Unger's 30K antibody (16) . Plasma glucose was measured by glucose autoanalyzer (Beckman Instruments, Inc., Fullerton, CA) using a glucose oxidase method. The specific activity of[3-3HJ glucose was measured as previously reported (17) using plasma deproteinized by the Somogyi method (18) . Calculations
The flux of glucose and hormones in each vessel was (19, 20) . Because the total glucose appearance is the sum of the amount of glucose infused and the residual endogenous glucose production, the latter was derived by subtracting the amount infused from the total appearance (all expressed in milligrams per kilogram per minute). Net glucose release into the portal system. Although the same size of glucose load was given in both experiments, less glucose was released into the portal system in the dexamethasone-treated dogs (Fig. 3) . Of the total glucose administered, 76±4% was released into the portal system in the control animals as compared with 55±4% in the steroid-treated dogs. The the controls was 9.2±1.6 mg/kg per min at 20 min as compared with 7.0±0.9 mg/kg per min at 45 min in the steroid-treated dogs. Despite the lower absorption ofglucose in the latter group, the hyperglycemia achieved was comparable ( After oral glucose administration, the liver changed from net output to net uptake. Despite the reduced release of glucose into the portal system, the net hepatic uptake by the dexamethasonetreated dogs was somewhat greater than in the control dogs, although the difference did not reach statistical significance. Of the total glucose released into the portal system, 27±4% was retained by the liver in the control dogs as compared with 53±13% in the steroid-treated dogs. On an absolute basis the control dogs retained 4.5±0.9 g glucose in the liver as compared with 7.0±1.9 g in the steroid-treated dogs. Accordingly, the net splanchnic glucose output after oral glucose was significantly greater in the control dogs as compared with the steroid-treated animals (Fig. 4) Insulin levels and balance. The basal insulin levels in the portal vein of the control dogs (32±7 IAU/ml) exceeded those in the hepatic vein (15±3 ALU/ml) and femoral artery ( 1±2 ytU/ ml) and were significantly less than in the steroid-treated dogs (63±6, 44±5, and 32±5 gU/ml, respectively) (Fig. 5) . After oral glucose administration, portal vein insulin levels rose to a maximum of 211±32 ,U/ml at 45 min in the steroid-treated dogs and to 147±51 sU/ml at 10 min in the controls. Arterial insulin levels were also higher (66±6 MU/ml vs. 48±10 uU/ml at 20 min). Net nonhepatic splanchnic insulin balance ( in the control dogs, significantly greater than in the steroid-treated dogs (22±4%) (Fig. 7) . After oral glucose administration, a similar increase in fractional hepatic extraction occurred in both groups. However, in view of their lower basal values, the increase remained significantly less in the steroid-treated dogs than in the control dogs at 10, 75, and 105 min. Glucagon levels and balance. Basal plasma glucagon levels were similar in the control and dexamethasone-treated dogs in all three blood vessels: 337±44 and 395±106 pg/ml in the portal vein; 265±42 and 257±62 pg/ml in the hepatic vein; and 215±29
Statistics
and 228±54 pg/ml in the femoral artery (Fig. 8) . After oral glucose administration, glucagon levels in the portal vein decreased to a nadir of 146±34 pg/ml at 90 min. The suppression in the steroid-treated dogs was slightly less, to a nadir of 214±47 pg/ ml at 105 min. A similar trend was observed with the absolute amounts reaching and leaving the liver. The fractional hepatic extraction of glucagon was 14±6% and 22±4% during the basal state, in the control and steroid-treated dogs respectively, and did not change significantly throughout the experiments in either group (data not shown).
Steady-state insulin infusion with euglycemic clamp studies.
As in the dogs treated with steroids for 2 d, 7 d ofdexamethasone significantly increased the basal arterial glucose levels (91±2 mg/ dl, as compared with 76±3 mg/dl in the controls) (Fig. 9) . The basal portal vein insulin levels were significantly higher in the dogs treated with dexamethasone for 7 days (54±11 AU/ml as compared with 21±5 AU/ml before that treatment (Table I) (Fig. 8 B) . During the sequential infusion of insulin (1 mU/kg per min from 0 to 75 min and 2 mU/kg per min from 75 to 150 min), portal vein insulin increased to 81±3 AU/ml and 139±2 MU/ml in the steroid-treated dogs and to 68±1 and 127±2 MU/ml in the control study. The arterial levels increased to 39±1 and 65±2 MU/ml and to 27±1 and 51± 1 AU/ml, respectively. The levels achieved during both infusion periods were significantly higher in the Figure 9 . Insulin infusion into the portal system with euglycemic clamp. Rate of exogenous glucose infusion (A) and endogenous glucose production (B) in control and dexamethasone-treated (2 mg/d for 7 d) dogs.
glucose disposal was diminished in the dogs treated with dexamethasone and hepatic glucose production was suppressed to a lesser degree than in the control animals. Such results confirm the previous observation that the insulin resistance of glucocorticoid excess involves both reduced use ofglucose and decreased suppression by insulin of hepatic glucose output (2). The peripheral insulin resistance has been attributed to postreceptor defects, based on reduced insulin responsiveness (2) . Sensitivity has also been shown to be impaired, which suggests possible additional abnormalities of receptor binding (3). Similarly, at the hepatic level, the insulin resistance could be due to reduced insulin binding, or to intracellular events reducing the effectiveness of the insulin-receptor complex. In the present studies, hepatic insulin resistance was apparent in that during the basal period net hepatic glucose production was not suppressed in the dexamethasone-treated dogs despite significantly higher portal vein insulin concentrations. Methyl prednisolone has been shown to potentiate the ability of both epinephrine (21) and glucagon (22) to increase hepatic glucose output. In our studies epinephrine was not measured but glucagon levels were similar in control and dexamethasone-treated animals.
The apparent increased absolute rate of glucose appearance after 7 d of dexamethasone treatment as measured isotopically may reflect further development of resistance as compared with 2 d of dexamethasone, or alternatively may simply reflect increased futile cycling. Methyl prednisolone has been reported to increase futile cycling in dogs (23) and [3-3H] glucose is subject to this effect (24) . Direct evaluation ofthe effect ofglucocorticoid administration on hepatic insulin receptors has produced varied results. In cultured rat hepatocytes, dexamethasone stimulated insulin receptor synthesis, and depending on the conditions used, either inhibited or potentiated insulin action (25) . However, administration of ACTH or dexamethasone to rats significantly decreased hepatic insulin receptor binding (26, 27) , with some indication that the effect was tissue specific (26). Rizza et al. (2) found little change in insulin binding to erythrocytes or monocytes after cortisol infusion for 24 h but a significant shift to the right ofthe insulin dose response curve for suppression ofhepatic glucose production.
Dexamethasone treatment was associated with a significant reduction in basal fractional hepatic extraction of insulin. This represents the first time that we have observed any reduction in basal fractional hepatic extraction of insulin. This does not appear to be a nonspecific effect because the fractional hepatic extraction of glucagon was very similar to that which we have previously reported (1 1). The reason for such lower fractional hepatic extraction ofinsulin is unknown. Whereas the possibility that fractional hepatic extraction of insulin may be related to changes in portal vein blood flow has been considered (12, 28), basal portal vein flow was not diminished in the dexamethasonetreated dogs. It is possible that the reduced fractional hepatic extraction of insulin reflects decreased insulin receptor number or affinity (26, 27) . Although hepatic extraction of insulin is not the same as insulin degradation, with isolated hepatocytes, a close relationship existed between total cell-bound insulin and insulin degradation velocity (29, 30) . However, Caro and Amatruda reported that after 1 wk of dexamethasone, isolated rat hepatocytes exhibited increased insulin degradation, although the relationship between degradation velocity and total bound insulin persisted (31) .
After oral glucose administration, the fractional hepatic extraction of insulin significantly increased in the steroid-treated dogs. The increase was very similar to that observed in the control dogs but because it started from a lower basal value, the fractional hepatic extraction was still lower compared with the control dogs. The increased fractional hepatic extraction of insulin after oral glucose is similar to what we have reported previously (12).
In contrast to those results, the increase in the dogs treated with dexamethasone was not associated with the usual increase in portal vein blood flow after oral glucose. This provides some additional evidence that increased portal vein flow is not primarily responsible for the augmented fractional hepatic extraction of insulin (12, 25). These results are different from those in which atropine administration inhibited both the increased portal vein blood flow and augmented fractional hepatic extraction of insulin after oral glucose (32). It is not known why oral glucose failed to produce an increase in portal vein flow in the dexamethasone-treated dogs, similar to thse seen in the control group, although this failure could be related to the smaller glucose absorption into the portal system. Elevated insulin concentrations in conditions of glucocorticoid excess are usually attributed to increase insulin secretion in response to a rise in plasma glucose concentration (10) . As judged by net nonhepatic splanchnic insulin balance, dexamethasone treatment did not significantly increase insulin secretion in these studies either in the basal state or after oral glucose. Because basal arterial glucose levels were higher in the dexamethasone treated groups, an increased secretion rate might have been expected. It is possible that the increased stimulus to secretion was opposed by a direct inhibitory effect of the corticosteroid at the B-cell level (4-9). The hyperinsulinemia observed would appear to be more attributable in these dogs to the reduced hepatic extraction ofinsulin than to an increased rate of secretion.
Administration of dexamethasone produced several other changes in carbohydrate metabolism. The fraction of the oral glucose ingested by the dogs that was released into the portal vein was significantly less after 2 d of dexamethasone. The explanation for this is not apparent although it could reflect diminished absorption of glucose from the gastrointestinal tract or greater use of glucose by that tissue. The latter seems less likely because the nonhepatic splanchnic glucose balance was very similar in the basal state in both the steroid-treated and control dogs. Although the absolute amount of glucose released into the portal system was less in the dogs treated with dexamethasone, the fraction of glucose taken up by the liver was greater. This is consistent with the observation that the net splanchnic output of glucose was greater in the control dogs. The finding that the incremental increase in fractional hepatic extraction of insulin and hepatic uptake of glucose after oral glucose were similar in the two groups does not necessarily indicate a causal relationship between the two. The possible relationship between fractional hepatic extraction of insulin and hepatic glucose uptake has been discussed previously (12). The increased hepatic uptake of glucose by the liver could reflect a direct action of steroids on the deposition of glucose into glycogen. Cortisol induced increased glycogen synthesis after glucose feeding in rats (33) and activation ofglycogen synthetase in mice treated with prednisolone (34) has been reported. Although it is now believed that hepatic glycogen synthesis is largely via three carbon fragments rather than direct incorporation of glucose (35) , the effects of steroids on glycogen metabolism could be independent of the pathway of synthesis. The effect could also serve partially or totally to overcome reduced insulin receptor function if such occurs with steroid treatment.
